Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,367 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07262619RecruitingPhase 1/Phase 2
Study of EIK1005 for advanced solid tumors
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT07287085Recruiting
Increasing lung cancer screening in emergency patients
This study tests a program to help emergency department patients get screened for lung cancer. If you smoke or used to smoke, the study will see if a text message reminder can help you schedule a screening test.
Rochester, New YorkAges 50–80 - NCT07303894RecruitingPhase 2
Isoquercetin for ovarian cancer patients
This trial tests if a plant-based supplement called isoquercetin can help people with ovarian cancer when given alongside their first chemotherapy. It aims to see if it improves treatment results.
Commack, New YorkAges 18 years+ - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Brewster, New YorkAges 16 years+ - NCT01742143Recruiting
Helping underserved patients finish cancer treatment and feel better
This study tests a support program (ICCAN) designed to help people from underserved communities better complete chemotherapy or radiation and improve quality of life. It may help by connecting patients with practical resources and support during treatment.
Brooklyn, New YorkAges 21–80 - NCT02926690RecruitingPhase 1
MELK inhibitor safety study for advanced breast cancer
This Phase 1 study tests how safe a drug called an MELK inhibitor is in people with advanced breast cancer that has spread or cannot be removed with surgery. If you qualify, the study is focused on side effects and includes a special group for triple-negative breast cancer.
New York, New YorkAges 18 years+ - NCT03290534RecruitingPhase 2
Implantable radiation sheet for early-stage lung cancer
This Phase 2 study tests whether a permanently implanted, low-dose radiation “sheet” can be used to treat certain early-stage lung cancers. It may help shrink or control tumors while delivering radiation directly at the cancer site.
New York, New YorkAges 18 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Westbury, New YorkAges 18 years+ - NCT02087852Recruiting
Kidney cancer DNA registry for patients and family
This study collects DNA from adults with kidney cancer (or suspected kidney cancer), plus DNA from some family members and healthy controls. It helps researchers understand whether certain genetic changes might be linked to kidney cancer risk.
Commack, New YorkAges 18 years+ - NCT07454330Recruiting
Support program for Chinese cancer patients' quality of life
This trial tests a support program designed to improve quality of life for Chinese cancer patients and survivors. If you qualify, you'll join the program by phone or video call.
Commack, New YorkAges 18 years+ - NCT07459673RecruitingPhase 2
HER2-positive breast cancer trial using ctDNA to guide treatment
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
Commack, New YorkAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
New York, New YorkAges 18 years+ - NCT07631000RecruitingPhase 2
Cadonilimab with chemotherapy for stomach cancer surgery
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
Uniondale, New YorkAges 18 years+ - NCT07780903Recruiting
Digital program for young adult cancer survivors to learn about healthcare costs
This study tests a digital program to help young adult cancer survivors learn about managing healthcare costs. If you have finished active cancer treatment, you may be able to join.
New York, New YorkAges 18–39 - NCT07388524RecruitingPhase 3
Testing atezolizumab after surgery for early stage lung cancer
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
Camillus, New YorkAges 18 years+ - NCT06929286RecruitingPhase 3
Gene therapy vs standard care for bladder cancer after BCG fails
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
Commack, New YorkAges 21 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Albany, New YorkAges Up to 12 months - NCT06150417RecruitingPhase 2
Study of extra radiation for prostate cancer spread to few spots
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
New York, New YorkAges 18 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Bay Shore, New YorkAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
Brooklyn, New YorkAges 18 years+ - NCT06888388Recruiting
Safety of nipple-sparing mastectomy for women with high-risk genes
This study looks at the long-term safety of a type of breast surgery (nipple-sparing mastectomy) in women who carry certain inherited gene changes (BRCA1, BRCA2, PALB2, TP53, CDH1, or PTEN) that increase their risk of breast cancer. The goal is to understand how safe this surgery is over time for these women.
New York, New YorkAges 18–90 - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Commack, New YorkAges 18 years+ - NCT07768449Recruiting
Counseling support for older cancer survivors
This study tests a counseling program designed to help people 65 and older who have finished cancer treatment and are now cancer-free. It aims to improve emotional well-being and quality of life.
Commack, New YorkAges 65 years+ - NCT07421700RecruitingPhase 1/Phase 2
Study of PF-08634404 alone or with enfortumab vedotin for bladder cancer
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
Albany, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 17 studies
- Memorial Sloan Kettering Nassau · 10 studies
- Memorial Sloan Kettering Commack · 9 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 5 studies
- Memorial Sloan Kettering Westchester · 5 studies
- NYU Langone Health · 5 studies
- Columbia University Irving Medical Center · 3 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,367 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.